Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …

Clostridioides difficile infections (CDIs) have decreased in the past years, but since 2021,
some hospitals have reported an increase in CDI rates. CDI remains a global concern and …

Clostridioides difficile infection (CDI) remains a significant contributor to healthcare costs
and morbidity due to high rates of recurrence. Currently, available antibiotic treatment …

Abstract RBX2660 (fecal microbiota, live-jslm; REBYOTA®) is an emerging option for the
prevention of recurrent Clostridioides difficile infection (CDI) following standard of care …

Clostridioides difficile (C. difficile) is responsible for a spectrum of nosocomial/antibiotic-
associated gastrointestinal diseases that are increasing in global incidence and mortality …

Background Fecal microbiota transplantation (FMT) is an interventional approach to treat
chronic and recurrent Clostridioides difficile infection (CDI). However, there is insufficient …

Commercial probiotic strains inhibited C. difficile, and other Clostridium cultures with zones
14.2–78.9 mm. The highest inhibition was observed with commercial culture on C. difficile …

There is a continual debate on the pros and cons of broad-spectrum versus pathogen-
specific antibiotics. The unmet need for a solution for antimicrobial resistance (AMR) has put …

To investigate whether the polysaccharide component of the Traditional Chinese Medicine
(TCM) formula Lizhong decoction (LZD) has therapeutic effects and regulates gut microbiota …

Clostridium difficile infection (CDI) has been increasing due to the effect of recurrent
hospitalizations. The use of antibiotics has been shown to alter the gut microbiome and lead …